Well what can I say...still hold my shares. Volume has increased quite a bit recently. A lot of new shares on the market. The company is headed in the right direction. Gearing up to close up Phase 3 studies and building cash for the FDA approval. 2013 still looks very promising and should reach the target price of $8.